Zomedica Corp. (NYSE American: ZOM)
Interview update with Larry Heaton, CEO and President […]
Interview update with Larry Heaton, CEO and President […]
XRX-OXY-101 Study will inform the dose choice in the upcoming Phase 3 Clinical Trial […]
Interview with Philip Sassower, Chief Executive Officer and Co-Chairman […]
Interview with Lewis Bateman, CEO
[…]
Company Continues to Build Through Channel Program, Sees Growth in 2023
[…]
Ottawa, Ontario–(Newsfile Corp. – November 22, 2022) – C-COM Satellite Systems Inc., (TSXV: CMI) (OTCQB: CYSNF) a leading global provider of commercial grade mobile auto-deploying satellite antenna systems, announced today that it will open a new R&D […]
Interview with Eric Schlorff, CEO and President […]
Acutus Medical, Inc’s (NASDAQ: AFIB) CEO David Roman recently spoke with Wall Street Analyzer to provide an overview of the company, discuss recent news, and go over key goals for the next 6-8 months. The company is focused on the treatment of atrial fibrillation and other cardiac arrhythmias and has a novel mapping system that enables physicians to visualize disease on a patient by patient basis and therefore has a higher success rate than current standard of care procedures. Mr. Roman went over AFIB’s recent Q3 results that included an over 50% increase in their international procedures and a 17% year to year growth in overall procedures. Perhaps the biggest announcement was the company’s deal with Medtronic for sale of their access portfolio, referred to as Left Heart Access (LHA), and consists of uncapped revenue based earn-outs for four years after the official launch. Acutus Medical produced $17.3 million in revenue in 2021. […]
Interview with Mark Kay, CEO and Chairman […]
Dr. Evans brings extensive strategic experience to advance search for XRx-008 Phase 3 development and commercialization partner […]
Copyright © 2019 The Wall Street Analyst, LLC. All rights reserved. Website by MyWebsiteSpot.com